A Phase 2 clinical trial led by Ludwig Harvard's Stephen Hodi and Ludwig Memorial Sloan Kettering (MSK)'s Jedd Wolchok has found that the combination of two immunotherapies for first - line treatment of advanced melanoma induces better responses and far longer progression - free survival than giving one of those drugs alone. (sciencedaily.com)
«It was approved in 2011 for first - line treatment of advanced melanoma in the US and Europe. (sciencedaily.com)
Moffitt Cancer Center researchers have laid the groundwork for a revolutionary new combination therapy for the treatment of advanced melanoma — melanoma that can not be removed surgically or has spread to other areas of the body. (sciencedaily.com)